Table 3. The mean percentage of PB CD3+/CD4+/CD152+ cells and CD3+/CD8+/CD152+ cells before and after 24, 48, 72, 96 and 120 h of anti-CD3+rIL-2 stimulation in patients with B-CLL and healthy controls.

	Time (h)
	0	24	48	72	96	120	P
CD3+/CD4+/CD152+
B-CLL patients (n=33)	11.8±7.2%	19.8±11.0%	19.0±9.3%	18.2±8.2%	14.7±4.0%	9.9±4.2%	I : III=0.002
	(I)	(III)	(V)	(VII)	(IX)	(XI)	I : V=0.003
							III : V=NS
							V : VII=NS
							VII : IX=0.03
							IX : XI=0.01
Healthy controls (n=25)	3.0±0.8%	4.7±1.0%	7.2±2.0%	10.4±2.9%	3.2±0.5%	2.2±0.4%	II : IV=0.002
	(II)	(IV)	(VI)	(VIII)	(X)	(XII)	IV : VI=0.001
							II : VI=0.0003
							VI : VIII=0.01
							VIII : X=0.0001
							X : XII=NS
P	I : II=0.001	III : IV=0.0001	V : VI=0.0001	VII : VIII=0.0005	IX : X=0.001	XI : XII=0.001
CD3+/CD8+/CD152+
B-CLL patients (n=33)	12.5±7.8%	20.0±15.0%	20.7±10.5%	19.7±9.4%	17.5±8.0%	11.5±5.1%	I : III=0.02
	(I)	(III)	(V)	(VII)	(IX)	(XI)	I : V=0.002
							III : V=NS
							V : VII=NS
							VII : IX=NS
							IX : XI=0.0001
Healthy controls (n=25)	2.9±1.3%	6.1±2.0%	10.0±3.2%	12.0±3.9%	3.2±1.1%	2.0±0.7%	II : IV=0.008
	(II)	(IV)	(VI)	(VIII)	(X)	(XII)	IV : VI=0.004
							II : VI=0.0001
							VI : VIII=0.05
							VIII : X=0.0001
							X : XII=NS
P	I : II=0.0001	III : IV=0.0005	V : VI=0.0003	VII : VIII=0.02	IX : X=0.0001	XI : XII=0.0001